News & Press

Press Releases

Addressing patient needs through scientific driven innovation

We aspire to become a leading biopharmaceutical company that discovers and develops novel, differentiated therapies in cancer and beyond, addressing critical unmet needs for patients in China and worldwide.

Press Releases
Abbisko Therapeutics completed the First Patient Dose of Next-generation EGFR Exon20ins Inhibitor ABSK112
Feb 23, 2024
Merck Delegation Visited Abbisko Shanghai R&D Center
Feb 07, 2024
US$70 million Arrived! Abbisko Therapeutics Announced it Received Upfront Payment Pursuant to the Licensing Agreement for Pimicotinib (ABSK021) with Merck
Feb 06, 2024
Abbisko Therapeutics Announces that U.S. FDA Has Granted Fast Track Designation for Its CSF-1R Inhibitor Pimicotinib(ABSK021)
Dec 14, 2023
Abbisko Therapeutics Announced the Entry into a Licensing Agreement for Pimicotinib (ABSK021) with Merck
Dec 05, 2023
Abbisko presented two preclinical research results at the 35th International Molecular Targets and Cancer Treatment Conference (EORTC-NCI-AACR)
Oct 16, 2023
Abbisko Therapeutics Obtains Approval from U.S. FDA to Conduct Phase I Clinical Study of FGFR4 Inhibitor Irpagratinib (ABSK011)
Sep 25, 2023
Abbisko Therapeutic announces that its next-generation FGFR4 mutant inhibitor ABSK012 has been granted orphan drug designation in the US for the treatment of Soft Tissue Sarcoma
Apr 03, 2023
Abbisko Therapeutics Obtained Approval from U.S. FDA for Pivotal Global Multi-center Phase III Clinical Trial of CSF-1R Inhibitor Pimicotinib (ABSK021)
Mar 16, 2023
Abbisko Therapeutics Announces an Out-License Agreement with Allist for ABK3376
Mar 01, 2023
Abbisko therapeutic announces the IND approval by NMPA for its next-generation FGFR inhibitor ABSK121
Feb 22, 2023
EXPANDED ACCESS POLICY
Feb 01, 2023
Abbisko Therapeutics announces that US FDA has granted breakthrough therapy designation for its CSF-1R inhibitor Pimicotinib(ABSK021)
Jan 30, 2023
Abbisko Therapeutics Obtains Approval from The China NMPA to Conduct a Phase II Clinical Study of Pimicotinib (ABSK021)in cGVHD
Jan 17, 2023
Abbisko Therapeutics announces preliminary Phase I safety and efficacy results of Irpagratinib (ABSK011) in patients in second-line hepatocellular carcinoma with FGF19 overexpression
Dec 15, 2022
Abbisko Therapeutics announces preliminary Phase II safety and efficacy results of Fexagratinib (ABSK091) in patients with urothelial carcinoma
Dec 08, 2022
Preliminary Phase Ib results of ABSK021 for advanced TGCT will be published at the 2022 CTOS annual meeting
Nov 15, 2022
Abbisko Therapeutics completed the first patient enrollment in the Phase II clinical trial for ABSK091 in combination with BeiGene’s Tislelizumab in urothelial carcinoma
Nov 04, 2022
Abbisko Therapeutic announces the clinical trial approval granted by U.S. FDA for its next-generation FGFR inhibitor ABSK121
Nov 01, 2022
Abbisko Therapeutics obtained pivotal Phase III clinical trial approval for CSF-1R inhibitor ABSK021 from the CDE of NMPA
Oct 25, 2022
Abbisko Therapeutics Completed Dosing of First Patient in China for Its Small-Molecule PD-L1 Inhibitor ABSK043
Sep 27, 2022
Abbisko Therapeutics won the 2022 "Future Star" Award of the biopharmaceutical industry
Aug 15, 2022
Abbisko Therapeutics announces China NMPA breakthrough therapy designation granted for its CSF-1R inhibitor ABSK021
Jul 20, 2022
Abbisko Therapeutics Completed Dosing of First Patient for Its First-in-Class Highly Selective FGFR2/3 Inhibitor ABSK061
Jul 04, 2022
Abbisko Therapeutics Announces the Appointment of Dr. Zidong Zhang as CFO
May 16, 2022
Abbisko Therapeutics Declared Two Next-Generation Precision Oncology Preclinical Candidates and Will Present Multiple Discovery and Translational Research Results at AACR Annual Meeting 2022
Mar 11, 2022
Abbisko Therapeutics Has Obtained IND Approval for ABSK061, an Innovative and Highly Selective FGFR2/3 Inhibitor, from the NMPA
Mar 03, 2022
Abbisko Therapeutics Announces Clinical Supply Agreement with BeiGene to Evaluate ABSK091 in Combination with Tislelizumab
Feb 15, 2022
Abbisko Therapeutics Completes Dosing of the First Patient in the Phase II Clinical Trial for ABSK011 in Combination with an Anti-PD-L1 Antibody
Feb 08, 2022
View all
we discover and develop first-in-class and best-in-class therapies
to address critical unmet needs for cancer patients in China and globally
Media
Bioworld: Abbisko out-licenses pimicotinib to Merck KGaA in $605M deal
Dec 12, 2023
Endpoints: Abbisko signs $70M upfront deal with Merck KGaA for PhIII cancer drug
Dec 05, 2023
FierceBiotech:Merck KGaA buys into Abbisko’s late-stage joint tumor med for $70M upfront
Dec 05, 2023
HEALTHY GEM:Abbisko Therapeutics Announces An Out-License Agreement With Allist For ABK3376
Mar 17, 2023
Bioworld:FDA grants breakthrough therapy designation to Abbisko's CSF­ 1R inhibitor, pimicotinib
Jan 30, 2023
Bioworld:Abbisko out-licenses preclinical EGFR candidate to Allist for $188M
Mar 03, 2023
AP NEWS: Abbisko Therapeutics announces that US FDA has granted breakthrough therapy designation for its CSF-1R inhibitor Pimicotinib(ABSK021)
Jan 31, 2023
TIME: Abbisko Therapeutics Obtains Approval from The China NMPA to Conduct a Phase II Clinical Study of Pimicotinib (ABSK021) in cGVHD
Jan 19, 2023
Abbisko Therapeutics Obtained ABSK091 IND Approval from NMPA
Dec 14, 2020
Abbisko Therapeutics’ Partner X4 Pharmaceuticals Presented Positive Clinical Data from Phase 2 Study of Mavorixafor in WHIM Syndrome
Jun 19, 2020
Abbisko Therapeutics Completes Dosing of the First Patient Cohort for ABSK-021 and The First Patient Enrollment for ABSK-011
Apr 07, 2020
Abbisko Therapeutics Enters into Licensing Agreement with AstraZeneca for Development and Commercialization of AZD4547
Nov 08, 2019
View all

Tel:(+86) 021-68912098

E-Mail:Bd@abbisko.com
    PR@abbisko.com
    IR@abbisko.com

Copyright © 2021 All rights reserved:Abbisko Therapeautics     沪ICP备17056565号-1